- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.05. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 312 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 16.04. | Optimistische Prognose für Sartorius Stedim Biotech von RBC bestätigt | 1 | IT BOLTWISE | ||
| SARTORIUS STEDIM BIOTECH SA ADR Aktie jetzt für 0€ handeln | |||||
| 16.04. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech publishes unaudited first quarter results for 2025 | 475 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Quarter Results/Forecast
Sartorius Stedim Biotech publishes unaudited first quarter results for 2025 16-Apr-2025 / 07:00 CET/CEST
... ► Artikel lesen | |
| 01.04. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 430 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 25.03. | Sartorius Stedim Biotech S.A.: Resolutions of the Combined Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A. | 666 | Dow Jones News | DJ Resolutions of the Combined Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.
Sartorius Stedim Biotech SA / Key word(s): AGM/EGM
Resolutions of the Combined Annual Shareholders'... ► Artikel lesen | |
| 05.03. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 384 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 17.02. | Sartorius Stedim Biotech SA: Information on Document Availability | 439 | Dow Jones News | DJ Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Information on Document Availability
17-Feb-2025 / 10:56 CET/CEST... ► Artikel lesen | |
| 17.02. | Sartorius Stedim Biotech releases Universal Registration Document 2024 | 345 | Dow Jones News | DJ Sartorius Stedim Biotech releases Universal Registration Document 2024
Sartorius Stedim Biotech SA / Key word(s): Annual Results
Sartorius Stedim Biotech releases Universal Registration Document... ► Artikel lesen | |
| 07.02. | Sartorius Stedim Biotech SA: Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders' Meeting | 534 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Dividend
Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders'... ► Artikel lesen | |
| 04.02. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 425 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 28.01. | Sartorius Stedim Biotech Preliminary FY24 Profit Declines | 6 | RTTNews | ||
| 28.01. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024 | 3.098 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Annual Results/Quarter Results
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024 28-Jan-2025 / 07:04... ► Artikel lesen | |
| 07.01. | Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech | 475 | Dow Jones News | DJ Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year liquidity contract statement... ► Artikel lesen | |
| 06.01. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 413 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 03.12.24 | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 329 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 25.11.24 | Sartorius Stedim Biotech eröffnet neues Zentrum für Bioprozess-Innovation in Marlborough, USA | 14 | Bionity.com | ||
| 22.11.24 | Sartorius Stedim Biotech Opens New Innovation Center in Massachusetts | 4 | Contract Pharma | ||
| 04.11.24 | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 360 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 17.10.24 | Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2024 | 699 | Dow Jones News | DJ Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2024
Sartorius Stedim Biotech SA / Key word(s): 9 Month figures
Sartorius Stedim Biotech publishes unaudited... ► Artikel lesen | |
| 01.10.24 | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 374 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 62,60 | 0,00 % | Tempus AI: Starkes Wachstum - Verluste steigen jedoch weiter an | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das erste Quartal 2025 bekannt gegeben und ein rasantes Wachstum vorgelegt. Tempus AI - Aktie:... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,075 | 0,00 % | Laufende Fusionskontrollverfahren: Merck KGaA, Darmstadt; Erwerb sämtlicher Anteile an und der alleinigen Kontrolle über SpringWorks Therapeutics, Inc., Stamford, Connecticut, USA | Datum der Anmeldung:08.05.2025Aktenzeichen:B3-54/25Unternehmen:Merck KGaA, Darmstadt; Erwerb sämtlicher Anteile an und der alleinigen Kontrolle über SpringWorks Therapeutics, Inc., Stamford, Connecticut... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,250 | 0,00 % | Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock | ||
| SUMMIT THERAPEUTICS | 23,070 | 0,00 % | Summit Therapeutics Q1 2025 slides: Strong cash position supports advancing Ivonescimab pipeline | ||
| SEPTERNA | 10,100 | 0,00 % | Novo und Septerna kooperieren bei oralen Adipositas-Medikamenten | DJ Novo und Septerna kooperieren bei oralen Adipositas-Medikamenten
Von Dominic Chopping
DOW JONES--Das dänische Pharmaunternehmen Novo Nordisk hat eine Kooperationsvereinbarung mit dem US-Biotechunternehmen... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 13,640 | +0,29 % | Arcutis Biotherapeutics, Inc.: New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice | ||
| ADMA BIOLOGICS | 19,200 | -1,39 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| ARCELLX | 58,40 | 0,00 % | Arcellx GAAP EPS of -$1.13, revenue of $8.1M | ||
| AVIDITY BIOSCIENCES | 28,980 | +2,04 % | Avidity Biosciences stock price target cut to $68 by H.C. Wainwright | ||
| JANUX THERAPEUTICS | 23,290 | 0,00 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
| TAYSHA GENE THERAPIES | 2,560 | +8,02 % | Baird maintains Outperform on Taysha stock, reiterates $7 target | ||
| PHATHOM PHARMACEUTICALS | 3,480 | 0,00 % | Phathom Pharmaceuticals surges 50% following large insider purchase | ||
| TARSUS PHARMACEUTICALS | 43,480 | +1,35 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| NUVALENT | 71,06 | 0,00 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results | Topline pivotal data expected for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population in the first half of 2025 in support of anticipated first NDA submission... ► Artikel lesen | |
| EVOTEC | 7,152 | +2,52 % | Biotech Report: Evotec fest, Biontech leichter | (shareribs.com) Frankfurt / New York 09.05.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Evotec legten deutlich zu. Qiagen und Biontech gaben nach. Auch an der Wall Street verlor... ► Artikel lesen |
SARTORIUS STEDIM BIOTECH SA ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 19,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SARTORIUS STEDIM BIOTECH SA ADR finden Sie auf Wallstreet Online.